知识与财富的链接
正套细胞淋巴瘤(mantle cell lymphoma,MCL)是一种B细胞淋巴瘤亚类,占非霍奇金淋巴瘤的6%~8%~([1])。MCL起源于淋巴滤泡外套区,特征是细胞遗传学染色体易位t(11;14)(q13;q32),导致bcl-1基因连接到免疫球蛋白重链增强子区引起Cyclin D1核内过度表达~([2])。MCL患者以老年男性为主,结外侵犯常见,兼具侵袭性淋巴瘤的侵袭性和惰性淋巴瘤的不可治愈性特点。虽然MCL有许多可用的治疗方案,但没有最佳的治疗方案,暂
Mantle cell lymphoma (MCL) accounts for about 6% of all non-Hodgkin lymphomas,and it is hard to be treated.Lenalidomide,a novel immunomodulatory agent,is a kind of thalidomide derivative.Many clinical studies have shown that lenalidomide has a good efficacy for many kinds of blood and lymphatic system diseases,and it has minor adverse events.This paper expounds the clinical research and application of lenalidomide in mantle cell lymphoma.
